Am. J. Respir. Crit. Care Med., Volume 157, Number 4, April 1998, 1324-1327

Bacillus Calmette-Guérin Revaccination Questionable with Low Tuberculosis Incidence

MARIANNA M. TALA-HEIKKILÄ, JUHANI E. TUOMINEN, and EERO O. J. TALA

Department of Paediatrics, Turku University Central Hospital, and Department of Biomedicine, University of Turku, Turku; and Department of Diseases of the Chest, Paimio Hospital, Preitilä, Finland

Bacillus Calmette-Guérin (BCG) revaccination was discontinued in Finland in 1990. The objective of this study was to assess the impact of BCG revaccination of tuberculin-negative school-children in prevention of tuberculosis. The tuberculosis cases in 1990-1995 were calculated among age cohorts born 1979-1984 and no longer covered by the BCG revaccination program. Corresponding data were collected for comparison from the period of revaccination in 1980-1985 among age cohorts born in 1969-1974. The National Tuberculosis Register was reviewed in order to observe the tuberculosis trend since 1980 in the age groups of 10-14 and 15-19 yr. Three cases of tuberculosis have been registered among non-BCG-revaccinated children during 6 yr after discontinuation of the program, i.e., 2.23 cases (95% CI 0.72 to 6.90) per million person yr. The control group revealed five cases, 3.78 (95% CI 1.57 to 9.07) per million person yr. The relative risk of tuberculosis in non-BCG-revaccinated children is 0.59 (95% CI 0.14 to 2.47) compared with the control group. The incidence of tuberculosis has continued to decline among adolescents since 1980. The follow-up data confirm that the cessation of BCG revaccination program had no effect on the continuing overall decline of tuberculosis in Finland. The efficacy of BCG revaccination seems to be low or nonexistent in countries with low tuberculosis incidence. Tala-Heikkilä MM, Tuominen JE, Tala EOJ. Bacillus Calmette-Guérin revaccination questionable with low tuberculosis incidence.

This article has been cited by other articles:

				C. A. Cosgrove, L. R. R. Castello-Branco, T. Hussell, A. Sexton, R. Giemza, R. Phillips, A. Williams, G. E. Griffin, G. Dougan, and D. J. M. Lewis Boosting of Cellular Immunity against Mycobacterium tuberculosis and Modulation of Skin Cytokine Responses in Healthy Human Volunteers by Mycobacterium bovis BCG Substrain Moreau Rio de Janeiro Oral Vaccine Infect. Immun., April 1, 2006; 74(4): 2449 - 2452. [Abstract] [Full Text] [PDF]

				M. A. Horwitz, G. Harth, B. J. Dillon, and S. Maslesa-Galic Enhancing the Protective Efficacy of Mycobacterium bovis BCG Vaccination against Tuberculosis by Boosting with the Mycobacterium tuberculosis Major Secretory Protein Infect. Immun., August 1, 2005; 73(8): 4676 - 4683. [Abstract] [Full Text] [PDF]

				B. M. Buddle, D. N. Wedlock, N. A. Parlane, L. A. L. Corner, G. W. de Lisle, and M. A. Skinner Revaccination of Neonatal Calves with Mycobacterium bovis BCG Reduces the Level of Protection against Bovine Tuberculosis Induced by a Single Vaccination Infect. Immun., November 1, 2003; 71(11): 6411 - 6419. [Abstract] [Full Text] [PDF]

				J.F. Broekmans, G.B. Migliori, H.L. Rieder, J. Lees, P. Ruutu, R. Loddenkemper, and M.C. Raviglione European framework for tuberculosis control and elimination in countries with a low incidence: Recommendations of the World Health Organization (WHO), International Union Against Tuberculosis and Lung Disease (IUATLD) and Royal Netherlands Tuberculosis Association (KNCV) Working Group Eur. Respir. J., April 1, 2002; 19(4): 765 - 775. [Abstract] [Full Text] [PDF]